Early-stage focus Mnemo Therapeutics is a Paris-based biotech with a small team (11-50 employees) and a heavy focus on preclinical discovery for tumor-specific targets (E-antigens) and multiple modalities (cell therapy, TCE, ADC, vaccine). This signals a potential upsell opportunity for collaborative research services, discovery partnerships, and early-stage translational support.

Platform leverage The company operates the EnfiniT integrated drug discovery engine combining in-silico and wet-lab pipelines. Sales opportunities exist in advanced computational biology tools, data integration services, biomarker discovery, and platform licensing to accelerate their target pipeline.

Immunotherapy focus Mnemo’s emphasis on immunotherapies and memory differentiation via epigenetic modulation (SUV39H1) indicates a potential need for epigenetics assays, high-content screening, and CAR-T related manufacturing support, as well as partnerships for preclinical model development.

Strategic partnerships Historical founding partners and key hires in business and immunology roles suggest opportunities for BD activities around co-development, funding rounds, and joint venture possibilities, especially with entities seeking access to novel E-antigen targets or CAR-T enhancements.

Funding signals With a $90M Series A and ongoing preclinical programs, Mnemo may require senior CRO/CMO partnerships, clinical-ready supply chain planning, and scalable manufacturing discussions for potential transition to IND-enabling studies, presenting a pathway for service-based or alliance-based engagements.